Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HK2 | P52789 | 5/20 | 0.43 |
| ▸ | HK1 | P19367 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.36 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.36 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.36 |
| ▸ | PYGB | P11216 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22658152 | 1.00 | CA1 (0.47) | CA1CA2CA9CA12KDM4E | |
| SCHEMBL15966301 | 1.00 | CA1 (0.47) | CA1CA2CA9CA12KDM4E | |
| SCHEMBL1548304 | 1.00 | CA1 (0.47) | CA1CA2CA9CA12KDM4E | |
| SCHEMBL23631140 | 1.00 | CA1 (0.47) | CA1CA2CA9CA12KDM4E | |
| SCHEMBL15966283 | 1.00 | CA1 (0.47) | CA1CA2CA9CA12KDM4E | |
| SCHEMBL22988698 | 1.00 | CA1 (0.47) | CA1CA2CA9CA12KDM4E | |
| SCHEMBL1548307 | 1.00 | CA1 (0.47) | CA1CA2CA9CA12KDM4E | |
| SCHEMBL15965645 | 1.00 | CA1 (0.47) | CA1CA2CA9CA12KDM4E | |
| Sulfuric Acid SCHEMBL21062202 | 0.98 | CA1 (0.46) | CA1CA2CA9CA12KDM4E | |
| SCHEMBL10325036 | 0.84 | KDM4E (0.49) | CA1CA2CA9CA12KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 979 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122012440-A | Heparin 3-O-sulfate transferase mutant with high enzyme activity and high thermal stability, and encoding gene and application thereof | 山东大学 | 2026-05-12 | — | — | CN | claimed |
| EP-4737469-A1 | NUCLEIC ACID CONJUGATES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Siran Biotechnology Co., Ltd. (CN) | 2026-05-06 | — | — | EP | claimed |
| US-12569512-B2 | Heparan sulfate (HS) oligosaccharides effect in liver ischemia reperfusion injury | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2026-03-10 | — | — | US | claimed |
| US-12540323-B2 | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | Suzhou Ribo Life Science Co., Ltd. (CN) | 2026-02-03 | — | — | US | claimed |
| US-12497622-B2 | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | Suzhou Ribo Life Science Co., Ltd. (CN) | 2025-12-16 | — | — | US | claimed |
| US-12496347-B2 | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof | Suzhou Ribo Life Science Co., Ltd. (CN) | 2025-12-16 | — | — | US | claimed |
| EP-4628583-A1 | BICYCLIC ABASIC NUCLEIC ACID ANALOGS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2025-10-08 | — | — | EP | claimed |
| US-12428642-B2 | Nucleic acid, composition and conjugate comprising the same, preparation method and use thereof | Suzhou Ribo Life Science Co., Ltd. (CN) | 2025-09-30 | — | — | US | claimed |
| EP-3672603-B1 | COMBINATION OF A MAPK/ERK PATHWAY INHIBITOR AND A GLYCOSAMINOGLYCAN FOR THE TREATMENT OF CANCER | Cell Receptor AG (CH) | 2025-09-24 | — | — | EP | claimed |
| US-20250188506-A1 | ANTICOAGULANT HEPARIN-CHONDROITIN CHIMERIC SACCHARIDE MOLECULE AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF | SHANDONG UNIVERSITY (CN) | 2025-06-12 | — | — | US | claimed |
| WO-2014179626-A2 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | claimed |
| EP-2751270-A1 | OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE | Isis Pharmaceuticals, Inc. (US) | 2014-07-09 | — | — | EP | claimed |
| US-20140066402-A1 | Pharmaceutical Compositions with Glycosaminoglycans and Use Thereof in the Treatment of Chronic Ulcers | LABORATORIOS FARMACEUTICOS ROVI S.A. (ES) | 2014-03-06 | — | — | US | claimed |
| WO-2013033230-A1 | OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | WO | claimed |
| EP-2308497-A1 | PHARMACEUTICAL COMPOSITION WITH GLYCOSAMINOGLYCANS AND USE THEREOF IN THE TREATMENT OF CHRONIC ULCERS | LABORATORIOS FARMACEUTICOS ROVI, S.A. (ES) | 2011-04-13 | — | — | EP | claimed |
| US-5849722-A | Oligosaccharide having affinity for fibroblast growth factor and process for producing same | SEIKAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-12-15 | — | — | US | claimed |
| EP-0509517-B1 | Oligosaccharide having affinity for fibroblast growth factor and process for producing same | SEIKAGAKU KOGYO CO LTD (JP) | 1997-01-29 | — | — | EP | claimed |
| EP-0509517-A2 | Oligosaccharide having affinity for fibroblast growth factor and process for producing same | SEIKAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1992-10-21 | — | — | EP | claimed |
| EP-0014184-B2 | HEPARIN FRAGMENTS HAVING A SELECTIVE ANTICOAGULATION ACTIVITY AND PROCESS FOR THEIR PREPARATION | Kabi AB (SE) | 1989-10-18 | — | — | EP | claimed |
| EP-0014184-B1 | HEPARIN FRAGMENTS HAVING A SELECTIVE ANTICOAGULATION ACTIVITY AND PROCESS FOR THEIR PREPARATION | Kabi AB (SE) | 1984-08-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569512-B2 | Heparan sulfate (HS) oligosaccharides effect in liver ischemia reperfusion injury | HPSE, GYS2, IRS1 | CA1 1618/4885CA2 3171/4885CA9 2880/4885 |
| US-20140066402-A1 | Pharmaceutical Compositions with Glycosaminoglycans and Use Thereof in the Treatment of Chronic Ulcers | CD44, MMP7, MATR3 | CA1 4832/4885CA2 4176/4885CA9 2574/4885 |
| US-12540323-B2 | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | PCSK9, APOB, NSUN2 | CA1 3457/4885CA2 3299/4885CA9 602/4885 |
| US-20250188506-A1 | ANTICOAGULANT HEPARIN-CHONDROITIN CHIMERIC SACCHARIDE MOLECULE AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF | HPSE, CD44, CSGALNACT1 | CA1 316/4885CA2 1103/4885CA9 300/4885 |
| US-12497622-B2 | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | F13A1, F13B, F11 | CA1 1955/4885CA2 3889/4885CA9 671/4885 |
| US-12428642-B2 | Nucleic acid, composition and conjugate comprising the same, preparation method and use thereof | TEK, TIE1, IGF2BP3 | CA1 4826/4885CA2 4803/4885CA9 3369/4885 |
| US-12496347-B2 | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof | APOB, PCSK9, APOL1 | CA1 4609/4885CA2 4714/4885CA9 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.